Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05997693 · ClinicalTrials.gov registry record · Phase 3
One-Month DAPT in CABG Patients
A Phase 3 study of Chronic Coronary Disease, sponsored by Weill Medical College of Cornell University.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 700
- Enrollment target
- 20
- Study locations
NCT05997693 is a Phase 3 study of Chronic Coronary Disease that is actively recruiting participants, run by Weill Medical College of Cornell University. The registered enrollment target is 700 participants. The trial reports 20 study locations across 7 states.
The verdict
NCT05997693, a Phase 3 study of Chronic Coronary Disease, is actively recruiting participants, sponsored by Weill Medical College of Cornell University.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 700 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
Conditions Studied
Interventions
- DRUG Low-dose aspirin
- DRUG Ticagrelor 90 MG
Study Locations (20)
Other
- Medical University Graz - Graz
- Johannes Kepler University Linz - Linz
- Medical University of Vienna - Vienna
- Beijing Anzhen Hospital - Beijing
- Center China Fuwai Hospital - Beijing
- University Hospital of Düsseldorf - Düsseldorf
- Westdeutsches Herz- und Gefäßzentrum Essen, Universität Duisburg-Essen - Essen
- Klinik für Herz- und Gefäßchirurgie - Universitäts-Herzzentrum Freiburg - Bad Krozingen - Freiburg im Breisgau
- University Hospital Giessen - Giessen
- Jena University Hospital - Jena
- LMU Klinikum Campus Großhadern - München
- Robert-Bosch-Krankenhaus Stuttgart - Stuttgart
- Sahlgrenska University Hospital - Gothenburg
New York
- NewYork-Presbyterian: Queens Hospital - Flushing
- Weill Cornell Medicine - New York
New Jersey
- Englewood Hospital - Englewood
Innsbruck
- Medical University Innsbruck - Innsbruck
Ontario
- University of Ottawa Heart Institute - Ottawa
China
- Ruijin Hospital: Shanghai Jiao Tong University School of Medicine - Shanghai
Jilian
- Jilin Heart Hospital - Changchun
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 700 participants |
| Start Date | 2024-08-15 |
| Est. Completion | 2031-01 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05997693
The ClinicalTrials.gov registry entry for NCT05997693 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 700 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Weill Medical College of Cornell University, which has 701 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Chronic Coronary Disease appearing as the primary indexed condition, and to 2 interventions - of which Low-dose aspirin is the first listed.
NCT05997693 reports 20 study locations spanning 7 distinct geographic areas - top geographies include Other, New York, New Jersey.
Frequently Asked Questions
What is clinical trial NCT05997693 about?
NCT05997693 is a clinical study titled "One-Month DAPT in CABG Patients". The purpose of this study is to compare the effect of ticagrelor plus low-dose aspirin versus low-dose aspirin alone in patients with chronic coronary disease undergoing coronary artery bypass grafting.
What is the current status of trial NCT05997693?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 700 participants. The study started on 2024-08-15. Estimated completion is 2031-01.
What conditions does trial NCT05997693 study?
This clinical trial studies the following conditions: Chronic Coronary Disease.
What interventions are being tested in trial NCT05997693?
The interventions under investigation include: Low-dose aspirin (DRUG), Ticagrelor 90 MG (DRUG).
Who is sponsoring clinical trial NCT05997693?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05997693 being conducted?
This trial has 20 study locations across New Jersey, New York, Innsbruck, Ontario, China. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.